A Phase I/II Clinical Trial to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-6768 in the Treatment of Patients With Advanced Solid Tumors
Latest Information Update: 22 May 2025
At a glance
- Drugs HRS 6768 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 14 May 2025 Status changed from not yet recruiting to recruiting.
- 21 Apr 2025 New trial record